Growth of Human Colorectal Cancer SW1116 Cells Is Inhibited by Cytokine-Induced Killer Cells

• Published in: Clinical & developmental immunology Vol. 2011; no. 2011; pp. 1 - 9
• Main Authors: Dai, Hanren, Wang, Yao, Li, Hong, Lv, Haiyan, Wang, Tao, Fu, Xiaobing, Han, Weidong
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Puplishing Corporation 01.01.2011; Hindawi Publishing Corporation; Hindawi Limited
• Subjects: Animals; Cancer therapies; Cell Line, Tumor; Clinical medicine; Colorectal cancer; Colorectal Neoplasms - pathology; Colorectal Neoplasms - therapy; Cytokine-Induced Killer Cells - immunology; Cytokine-Induced Killer Cells - transplantation; Cytotoxicity, Immunologic; Hospitals; Humans; Immunology; Immunophenotyping; Immunotherapy; Immunotherapy, Adoptive; Life sciences; Mice; Mice, Nude; Thoracic surgery; Transplantation, Heterologous; Tumors; United States > US
• ISSN: 1740-2522; 2314-8861; 1740-2530; 2314-7156
• DOI: 10.1155/2011/621414

Previous reports have suggested that treatment with cytokine-induced killer (CIK) cells may benefit patients with various types of tumor. The aim of this study was to evaluate the antitumor effects of CIK cells against the colorectal cancer line SW1116 in vitro and in vivo. CIK cells were generated routinely from peripheral blood mononuclear cells of healthy human donors, and the number of CD3+CD56+ cells was expanded more than 1300-fold after 14-day culture. At an effector : target cell ratio of 50 : 1, the percentage lysis of SW1116 cells reached 68% in the presence of CIK cells, Experimental mice injected with SW1116 cells subcutaneously were divided randomly into four groups: untreated, 5-fluorouracil (5-FU)-treated, CIK-consecutive treated (injected once/day) and CIK-interval treated (injected once every 5 days). CIK cells were injected abdominally five times in total. Compared with the untreated group, xenograft growth was inhibited greatly by CIK treatment, to nearly the same extent as with 5-FU treatment. We demonstrated that the necrotic area in the tumor xenograft was markedly larger in the CIK-treated groups than in the other groups. These findings suggest that CIK-based immunotherapy may represent an effective choice for patients with colorectal cancer.